Kiromic Biopharma Current Valuation vs. Cash Per Share

KRBPDelisted Stock  USD 2.68  0.07  2.55%   
Based on the key profitability measurements obtained from Kiromic Biopharma's financial statements, Kiromic Biopharma may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in January. Profitability indicators assess Kiromic Biopharma's ability to earn profits and add value for shareholders.
For Kiromic Biopharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Kiromic Biopharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Kiromic Biopharma utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Kiromic Biopharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Kiromic Biopharma over time as well as its relative position and ranking within its peers.
  
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.
Please note, there is a significant difference between Kiromic Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kiromic Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kiromic Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Kiromic Biopharma Cash Per Share vs. Current Valuation Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Kiromic Biopharma's current stock value. Our valuation model uses many indicators to compare Kiromic Biopharma value to that of its competitors to determine the firm's financial worth.
Kiromic Biopharma is rated below average in current valuation category among its peers. It is rated below average in cash per share category among its peers . The ratio of Current Valuation to Cash Per Share for Kiromic Biopharma is about  23,296,968 . Comparative valuation analysis is a catch-all technique that is used if you cannot value Kiromic Biopharma by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Kiromic Current Valuation vs. Competition

Kiromic Biopharma is rated below average in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is now estimated at about 308.2 Million. Kiromic Biopharma holds roughly 9.55 Million in current valuation claiming about 3% of equities under Health Care industry.

Kiromic Cash Per Share vs. Current Valuation

Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Kiromic Biopharma

Enterprise Value

 = 

Market Cap + Debt

-

Cash

 = 
9.55 M
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.

Kiromic Biopharma

Cash Per Share

 = 

Total Cash

Average Shares

 = 
0.41 X
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.

Kiromic Cash Per Share Comparison

Kiromic Biopharma is currently under evaluation in cash per share category among its peers.

Kiromic Biopharma Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Kiromic Biopharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Kiromic Biopharma will eventually generate negative long term returns. The profitability progress is the general direction of Kiromic Biopharma's change in net profit over the period of time. It can combine multiple indicators of Kiromic Biopharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell to target solid tumors. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas. Kiromic Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 59 people.

Kiromic Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Kiromic Biopharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Kiromic Biopharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Kiromic Biopharma's important profitability drivers and their relationship over time.

Use Kiromic Biopharma in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Kiromic Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kiromic Biopharma will appreciate offsetting losses from the drop in the long position's value.

Kiromic Biopharma Pair Trading

Kiromic Biopharma Pair Trading Analysis

The ability to find closely correlated positions to Kiromic Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Kiromic Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Kiromic Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Kiromic Biopharma to buy it.
The correlation of Kiromic Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Kiromic Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Kiromic Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Kiromic Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Kiromic Biopharma position

In addition to having Kiromic Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Beers Thematic Idea Now

Beers
Beers Theme
Companies involved in production and distribution of domestic and international beer. The Beers theme has 48 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Beers Theme or any other thematic opportunities.
View All  Next Launch
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.
You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.

Other Consideration for investing in Kiromic Stock

If you are still planning to invest in Kiromic Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kiromic Biopharma's history and understand the potential risks before investing.
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Fundamental Analysis
View fundamental data based on most recent published financial statements
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk